EndoQuest Robotics, a Texas-based medical device company, has secured $42 million in C-1 funding. Leading the round were CE Ventures, McNair Interests, and a new investor, Puma Venture Capital LLC.
The recently obtained funds will play a crucial role in propelling important projects, such as more R&D, regulatory milestones, commercialization endeavours, and strengthening the organization’s leadership in flexible endoluminal robotics.
Read also – Aurora-based GelSana Therapeutics Secures a New Funding of Undisclosed Amount
EndoQuest Robotics is a pioneer in the development of endoluminal robotic technologies, under the leadership of CEO Kurt Azarbarzin. It is concentrated on creating a cutting-edge robotic system that provides accuracy, adaptability, and better patient outcomes in order to fill the gaps in gastrointestinal (“GI”) and other endoluminal processes.
Read also – Johnson & Johnson MedTech Acquires Laminar, Inc
The company’s unique technology is made to manoeuvre and carry out operations inside the luminal regions of the body, enabling less invasive interventions and enhancing the skills of medical experts. The FDA has not approved EndoQuest’s Flexible Robotic System for commercial sale in the US, and it is still in the development stage.
About EndoQuest Robotics
The world’s first endoluminal robotic surgical system, the Endoluminal Surgical (ELS) System, was created by EndoQuest Robotics and enables therapeutic endoscopists and surgeons to perform upper and lower gastrointestinal surgery using a trans-oral or trans-anal approach in a less invasive manner.
Read also – Boston INNO4 Secures an Investment from ServicePoint
